Alimta
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
NICE approves lung cancer and leukaemia treatments
August 24, 2016Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed
The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
German Supreme Court grants Lilly appeal to block Alimta generics
June 15, 2016Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly
Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …
Lilly suffers damaging Alimta patent blow
February 15, 2016Manufacturing and Production, Sales and Marketing Actavis, Alimta, Allergan, Eli Lilly, pemetrexed
Eli Lilly says it plans to appeal a UK High Court’s verdict that could imminently open its blockbuster lung cancer …
Lilly defeats Teva in US court over Alimta patent
August 26, 2015Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer
Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …
UK Court weighs in on Lilly-Actavis Alimta case
June 26, 2015Medical Communications, Sales and Marketing Actavis, Alimta, UK, lilly
Actavis will be infringing Lilly’s patent if it were to produce generic versions of Alimta, the UK Court of Appeal …
German court rules against Lilly in Alimta patent case
March 10, 2015Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed
A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …
NICE rejects Alimta
February 28, 2014Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed
Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …
Lilly to go ‘on offense’
January 31, 2014Sales and Marketing Alimta, Lechleiter, cymbalta, lilly, q4, zyprexa
The loss of patent on antidepressant Cymbalta in the US last December was largely responsible for Eli Lilly & Co’s …
Lilly suffers late-stage cancer blow
September 10, 2012Research and Development, Sales and Marketing Alimta, Cancer, avastin, lilly, oncology
Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …
Alimta recommended as maintenance therapy
March 1, 2010Sales and Marketing Alimta, Cancer, NSCLC, lilly
NICE has recommended Alimta as a maintenance treatment for people with locally advanced or metastatic non-small cell lung cancer. Patients …
Latest content
FibroFind appoints Lee Borthwick as CEO
